

**FOR RELEASE, October 25, 2007**

**Contact :** Trinity Biotech plc  
Brendan Farrell  
(353)-1-2769800  
E-mail: [brendan.farrell@trinitybiotech.com](mailto:brendan.farrell@trinitybiotech.com)



## **Trinity Biotech Announces Quarter 3 Results Year to date revenues increase 26%**

**DUBLIN, Ireland (25 October, 2007)....** Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2007.

Revenues for the year to September 2007 increased 26% to US\$107.9 million compared to US\$85.3 million in the same period last year, in part reflecting the acquisition of bioMerieux in June 2006. Operating profit for the same period has increased to US\$8.3 million from US\$0.8 million. Excluding the impact of the US\$5.8m inventory write off in 2006 this represents an increase of 25%.

Profit after tax before inventory write-off for the nine months was US\$5.6 million compared to US\$5.9 million for the same period in 2006.

Revenues for the quarter were US\$33.7 million compared to US\$33.3 million in quarter 3, 2006. Operating profit for the quarter was US\$1.3 million, profit before tax was US\$0.6 million and profit after tax was \$0.03 million.

Revenues for the nine months by key product area were as follows :

	<b>2006 Q1-Q3</b>	<b>2007 Q1-Q3</b>	
	<b>US\$000</b>	<b>US\$000</b>	<b>% Increase</b>
Clinical Chemistry	11,128	12,364	11.1%
Haemostasis	29,828	46,822	57.0%
Infectious Diseases	32,109	30,975	(3.5%)
Point of Care	12,281	17,731	44.4%
<b>Total</b>	<b>85,346</b>	<b>107,892</b>	<b>26.4%</b>

Revenues for the nine months by geographic location were as follows :

	<b>2006 Q1-Q3</b>	<b>2007 Q1-Q3</b>	
	<b>US\$000</b>	<b>US\$000</b>	<b>% Increase</b>
USA	42,402	51,722	22.0%
Europe	23,957	33,025	37.9%
Asia / Africa	18,987	23,145	21.9%
<b>Total</b>	<b>85,346</b>	<b>107,892</b>	<b>26.4%</b>

Gross profit for the quarter amounted to US\$15.3 million representing a gross margin of 45.3%. This compares to a gross margin of 46% for the same period in 2006.

Research and development expenditure remains at approximately 5% of revenues whilst the increase in selling, general and administrative expenses from US\$10.3 million in 2006 to US\$12.1 million in the current year is primarily attributable to the full impact of the acquisition of the haemostasis product line of bioMerieux in June 2006 and the direct selling operation in France which was established in October 2006. The tax charge for the quarter represents an unusually high effective tax rate of 95% and is attributable to a deferred tax charge associated with inventory movements within the group during the quarter. The effective tax rate for the year to date is 12.8% which is broadly in line with expectations.

Commenting on the results, Rory Nealon, Chief Financial Officer, said “Notwithstanding that quarter 3 revenues have increased slightly over the same period in 2006 this quarter’s results were lower than expectations. Revenues have been impacted by lower flu antibody sales through our Fitzgerald operation. Similarly, seasonal factors have affected our haemostasis business where the traditional vacation period, particularly in Continental Europe, has resulted in a drop in revenues. The latter reflects a pattern which is consistent with the lower than expected haemostasis sales in quarter 3, 2006. On the positive side we expect that quarter 4 revenues will represent a significant increase over quarter 3 as these seasonal factors will not apply and given the strength of the current order book. During the quarter, the Company generated EBITDA and share option expense of US\$3.7 million and operating profits of US\$1.3 million.”

Ronan O’ Caoimh, CEO, commented, “The year to date has seen growth across all of the Company’s geographic locations and product areas with the exception of Infectious Diseases which has been affected by the lower demand for flu antibodies particularly in the Asian market. With the impact of outbreak related diseases and seasonal factors, revenues can be expected to exhibit some fluctuation, especially in the context of a short 13 week reporting cycle. However, it is anticipated that the key areas of growth identified by the Company of point of care, diabetes testing and haemostasis will make the Company less susceptible to such factors in the medium term.

During the quarter the Company was proud to celebrate 15 years of trading on the NASDAQ. The fifteen years have seen the Company grow into a position where we are now a leading participant in a number of segments of the diagnostic industry. In the field of haemostasis we are now one of the four major players and have a best in class instrument platform to complement our routine and speciality reagent product ranges. We are also particularly proud of our position in the point of care market where we are at the forefront of the fight against HIV/AIDS, particularly in the US and African markets. Also during these 15 years, the establishment of direct sales forces in the USA, Germany, United Kingdom and France, representing 60% of the world diagnostics market, have ensured that the Company now has control over the sale and marketing of its products and greater proximity to its ultimate customer base.”

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company’s periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own salesforce and a network of international distributors and strategic partners. For further information please see the Company’s website: [www.trinitybiotech.com](http://www.trinitybiotech.com).

**Trinity Biotech plc**  
**Consolidated Income Statements**

(US\$000's except share data)

	<b>Three Months Ended September 30, 2007 (unaudited)</b>	<b>Three Months Ended September 30, 2006 (unaudited)</b>	<b>Nine Months Ended September 30, 2007 (unaudited)</b>	<b>Nine Months Ended September 30, 2006 (unaudited)</b>
<b>Revenues</b>	<b>33,746</b>	<b>33,319</b>	<b>107,892</b>	<b>85,346</b>
Cost of sales	(18,439)	(17,962)	(57,149)	(44,296)
Cost of sales – inventory write off	-	-	-	(5,800)
Cost of sales – share based payments	(21)	(23)	(53)	(72)
<b>Gross profit</b>	<b>15,286</b>	<b>15,334</b>	<b>50,690</b>	<b>35,178</b>
<i>Gross profit before inventory write off</i>	<i>15,286</i>	<i>15,334</i>	<i>50,690</i>	<i>40,978</i>
Other operating income	91	36	256	157
Research & development expenses	(1,560)	(1,738)	(5,094)	(4,696)
Selling, general and administrative expenses	(12,131)	(10,344)	(36,448)	(28,904)
Indirect share based payments	(398)	(330)	(1,106)	(915)
<b>Operating profit</b>	<b>1,288</b>	<b>2,958</b>	<b>8,298</b>	<b>820</b>
<i>Operating profit before inventory write off</i>	<i>1,288</i>	<i>2,958</i>	<i>8,298</i>	<i>6,620</i>
Financial income	41	331	400	796
Financial expenses	(717)	(982)	(2,327)	(1,724)
<b>Net financing costs</b>	<b>(676)</b>	<b>(651)</b>	<b>(1,927)</b>	<b>(928)</b>
<b>Profit / (Loss) before tax</b>	<b>612</b>	<b>2,307</b>	<b>6,371</b>	<b>(108)</b>
Income tax (expense) / credit	(581)	244	(815)	1,786
<b>Profit for the period</b>	<b>31</b>	<b>2,551</b>	<b>5,556</b>	<b>1,678</b>
<i>Profit for the period before inventory write off</i>	<i>31</i>	<i>2,551</i>	<i>5,556</i>	<i>5,906</i>
Earnings per ADR (US cents)	0.2	13.8	29.2	9.7
Earnings per ADR before inventory write off	0.2	13.8	29.2	34.1
Diluted earnings per ADR (US cents)	0.2	13.5	28.5	9.7
Diluted earnings per ADR before inventory write off	0.2	13.5	28.5	33.2
Weighted average no. of ADR shares used in computing earnings per share	19,015,883	18,498,826	18,999,424	17,315,106

*The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company's accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).*

**Trinity Biotech plc**  
**Consolidated Balance Sheets**

	<i>September</i> <i>30, 2007</i> <i>US\$ '000</i> <i>(unaudited)</i>	<i>December</i> <i>31, 2006</i> <i>US\$ '000</i> <i>(audited)</i>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	24,767	22,255
Goodwill and intangible assets	127,364	121,768
Deferred tax assets	7,548	7,656
Other assets	96	76
<b>Total non-current assets</b>	159,775	151,755
<b>Current assets</b>		
Inventories	55,753	45,572
Trade and other receivables	26,016	33,115
Income tax receivable	479	368
Financial assets – restricted cash	-	15,500
Cash and cash equivalents	4,124	2,821
<b>Total current assets</b>	86,372	97,376
<b>TOTAL ASSETS</b>	246,147	249,131
<b>EQUITY AND LIABILITIES</b>		
<b>Equity attributable to the equity holders of the parent</b>		
Share capital	990	978
Share premium	153,942	151,774
Retained earnings	17,580	10,818
Translation reserve	131	(275)
Other reserves	3,967	3,967
<b>Total equity</b>	176,610	167,262
<b>Current liabilities</b>		
Interest-bearing loans and borrowings	10,605	10,382
Convertible notes – interest bearing	-	1,836
Income tax payable	398	44
Trade and other payables	19,885	20,459
Other financial liabilities	2,685	3,120
Provisions	100	100
<b>Total current liabilities</b>	33,673	35,941
<b>Non-current liabilities</b>		
Interest-bearing loans and borrowings	25,412	33,076
Other financial liabilities	-	2,568
Other payables	463	838
Deferred tax liabilities	9,989	9,446
<b>Total non-current liabilities</b>	35,864	45,928
<b>TOTAL LIABILITIES</b>	69,537	81,869
<b>TOTAL EQUITY AND LIABILITIES</b>	246,147	249,131

*The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company's accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).*